Universal CAR-T Cell Therapy for MM
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBioray Laboratories
About this trial
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Eligibility criteria
Qualifiers
Expected survival of at least 3 months;
Subjects should have measurable disease that meets the IMWG 2016 criteria;
Previously received at least two lines of prior anti-myeloma therapy ；
Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
Disqualifiers
Pregnant or breastfeeding women;
History of other malignant tumors;
Active autoimmune diseases requiring immunotherapy;
Previously received allogeneic stem cell transplantation;
Trial design
Treatments tested in this trial
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
Treatment groups
6 Participants
are divided into 1 treatment groupSponsors and collaborators
Bioray Laboratories
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborator
Source ClinicalTrials.gov